Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
Independent prescribing by health system pharmacists has decreased, but a survey shows greater involvement in emergency departments and an expanding role for pharmacy technicians.
Results presented at the 85th Scientific Sessions of the American Diabetes Association in Chicago highlight the potential for AI to detect disease before signs and symptoms occur.
There has been no or some progress in most areas since a National Institute of Health consensus development project in 2020, according to a group of experts. But exception is important: Prevention of moderate or severe chronic graft-vs.-host disease.
All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host disease prophylaxis.
The findings were consistent with those seen in a study of Western study participants.
Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Giving small-molecule drugs the same 13-year exemption from price negotiation as biologics would cost the federal government billions of dollars, argue three Harvard researchers
"All kinds of enhancements" have crept into claims from providers, Ronanki said, and health plans have responded. But his company is impartial about the net value and strives to make the claim accurate in the first place, he said.
National director of midwifery, Ob Hospitalist Group. Ob Hospitalist Group (OBHG) provides hospitals with obstetric services.
Ronanki says the differentiators for Lyric are a subscription-based model; being a platform that allows for technology integration and scale; and transparency.
Ben Scharfe, CPA, shares how his career-changing advice came from an unlikely person.
Executive vice president of artificial intelligence, Altera Digital Health. Altera Digital Health provides digital services to healthcare clients.
Manager of formulary operations and strategy, Yale Health. Yale Health is a not-for-profit, physician-led health maintenance organization that provides integrated, patient-centered care to the university community.
Vice president and market executive at Highmark Health. Highmark Health is a national health and wellness organization serving nearly 50 million Americans.
CEO at Serve You Rx. Serve You Rx is a midmarket pharmacy benefit manager (PBM) for self-funded employers.
Senior director of clinical programs at Capital Rx Capital Rx is an enterprise health technology company and public benefit Capital Rx is an enterprise health technology company and public benefit corporationbthat provides various healthcare benefit administration solutions for commercial, Medicare and Medicaid plans.
Vice president of postacute care solutions at OneHome. OneHome is a postacute services business for Medicare Advantage members offering engaged, at-risk network oversight for home healthcare, skilled nursing facilities, durable medical equipment and infusion services.
Director of clinical effectiveness and operations at Prime Therapeutics LLC. Prime Therapeutics is a pharmacy benefits manager owned by 19 Blue Cross and Blue Shield plans.
Chief of pharmacy at CareAllies. CareAllies is a population health company that supports physician practices and health plans.
Co-founder and chief clinical officer, InStride Health. InStride Health provides evidence-based care for children, teens and young adults with anxiety and obsessive-compulsive disorder (OCD) and their families.
Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article published in the American Journal of Hematology.
The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV infections.
Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, SAT-3247.
Satellos Bioscience's experimental small-molecule drug for Duchenne muscular dystrophy is showing positive results as a stand-alone treatment, but Phil Lambert, Ph.D., the company's chief scientific officer says the complexity of Duchenne muscular dystrophy may ultimately mean that a number of different therapies will be used together,
Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking behind it.
